

COVID-19 vaccines – ACIP recommends additional 2024-2025 vaccine doses for certain groups

- On October 23, 2024, the <u>Centers for Disease Control and Prevention's (CDC) Director endorsed</u>
 the CDC's <u>Advisory Committee on Immunization Practice's (ACIP)</u> recommendation for people 65
 years and older and those who are moderately or severely immunocompromised to receive a
 second dose of 2024 2025 COVID-19 vaccine six months after their first dose.
 - These updated recommendations also allow for flexibility for additional doses (ie, three or more) for those who are moderately or severely immunocompromised, in consultation with their healthcare provider (a strategy known as shared *clinical decision making*).
- The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults and those who are immunocompromised, along with the currently available data on vaccine effectiveness and year-round circulation of COVID-19.
- Updated vaccine administration recommendations may be found here.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.